



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Li et al.

Docket No.: PF126P2

Application No.: 09/901,910

Confirmation No.: 7856

Filed: July 11, 2001

Art Unit: 1635

For: Connective Tissue Growth Factor-2

Examiner: T. C. Gibbs

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of a claim of the subject application, Attorneys and/or Agents for Applicants hereby direct the Examiner's attention to references AK to AO listed on the attached Form PTO/SB/08. A copy of each reference is enclosed.

The listed references are presented so that the Patent and Trademark Office can determine any materiality thereof to the claimed invention. See 37 C.F.R. § 1.104(a) concerning the Examiner's duty to consider and use any such information. Applicants respectfully request that the Examiner make the listed references of record in the file history of the application, and consider the information contained therein during the prosecution of this application.

Identification of the listed references is not to be construed an admission of any individual associated with the filing or prosecution of the subject application that such references are available as "prior art" against the subject application. Furthermore, Applicants do not waive any rights to take appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the subject application.

Applicants believe that this Information Disclosure Statement is being filed after the period specified in 37 C.F.R. § 1.97(b), but before the mailing date of a final action under § 1.113, a notice of allowance under § 1.311, or an action that otherwise closes prosecution in the


application. Pursuant to 37 C.F.R. § 1.97(c), the Patent and Trademark Office will consider this Information Disclosure Statement if it is accompanied by the statement specified in 37 C.F.R. § 1.97(e).

Accordingly, the undersigned certifies pursuant to 37 C.F.R. § 1.97(e)(1) that each item of information contained in this Supplemental Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three (3) months prior to the filing of this Supplemental Information Disclosure Statement. Additionally, pursuant to 37 C.F.R. § 1.704(d), the undersigned certifies that each item of information contained in this Supplemental Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart application, and that this communication was not received by any individual designated in 37 C.F.R. § 1.56(c) more than thirty days prior to the filing of this Supplemental Information Disclosure Statement. In particular, the listed references were cited in a Supplementary European Search Report (reference AO herewith) dated December 2, 2004, in connection with a corresponding European patent application.


If any additional fees are deemed necessary, the Patent & Trademark Office is authorized to charge the required fee to our Deposit Account No. 08-3425.

Dated: December 17, 2004

Respectfully submitted,

By  _____
Mark J. Hyman

Registration No.: 46,789
HUMAN GENOME SCIENCES, INC.
Intellectual Property Dept.
14200 Shady Grove Road
Rockville, Maryland 20850
(240) 314-1224



PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	09/901,910-Conf. #7856
				Filing Date	July 11, 2001
				First Named Inventor	Haodong Li
				Art Unit	1635
				Examiner Name	T. C. Gibbs
Sheet	1	of	1	Attorney Docket Number	PF126P2

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	AK	XIE et al., "CYR61, an angiogenic inducer, is over-expressed and estrogen inducible in breast cancer." Proceedings of 91st Annual Meeting for Amer. Assoc. for Cancer Res., Vol. 41 (April 1, 2000)		
	AL	BABIC et al., "Fisp12/mouse connective tissue growth factor mediates endothelial cell adhesion and migration through integrin alphavbeta3, promotes endothelial cell survival, and induces angiogenesis in vivo." Mol Cell Biol. 1999 Apr;19(4):2958-66.		
	AM	JEDSADAYANMATA et al., "Activation-dependent adhesion of human platelets to Cyr61 and Fisp12/mouse connective tissue growth factor is mediated through integrin alpha(IIb)beta(3)." J Biol Chem. 1999 Aug 20;274(34):24321-7.		
	AN	SHIMO et al., "Inhibition of endogenous expression of connective tissue growth factor by its antisense oligonucleotide and antisense RNA suppresses proliferation and migration of vascular endothelial cells." J. Biochemistry v. 124(1) p. 130-140 (July 1998).		
	AO	Supplemental European Search Report for EP. App. No. EP 01 95 4638 (December 2, 2004).		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--